carbostyril has been researched along with Endometrial Neoplasms in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (77.78) | 24.3611 |
| 2020's | 2 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Aghajanian, C; Caird, I; Grisham, RN; Guillen, J; Hensley, ML; Hyman, DM; Iasonos, A; Makker, V; O'Cearbhaill, RE; Rubinstein, MM; Sabbatini, P; Seier, K; Selcuklu, SD; Soldan, K; Tew, WP; Torrisi, J; Troso-Sandoval, T; Won, H; Zimel, C | 1 |
| Che, X; Feng, W; Jia, N; Jiang, Y; Yang, T; Zhu, M | 1 |
| Anderson, L; Ayala, R; Finn, RS; Galderisi, C; Kolarova, T; Konecny, GE; Kristof, J; Luo, T; O'Brien, NA; Porta, DG; Qi, J; Qi, Z; Shi, MM; Slamon, DJ; Venkatesan, N; Winterhoff, B; Yang, G; Yovine, A | 1 |
| Blais, SP; Byron, SA; Chen, H; Dehkhoda, F; Gartside, MG; Loch, D; Mohammadi, M; Neubert, TA; Pollock, PM; Wortmann, A | 1 |
| Dolcet, X; Domingo, M; Dosil, MA; Eritja, N; Llombart-Cussac, A; Matias-Guiu, X; Mirantes, C; Santacana, M; Valls, J | 1 |
| Liu, H; Wang, L; Wang, T; Xiang, H; Xiao, H; Zeng, Y | 1 |
| Block, MS; Dowdy, SC | 1 |
| Finkler, N; Fong, PC; Garcia, AA; Konecny, GE; Kristeleit, R; Lee, PS; Lorusso, D; Mishra, K; Rocconi, RP; Squires, M; Upalawanna, A; Wang, Y | 1 |
| Flippot, R; Vignot, S | 1 |
2 trial(s) available for carbostyril and Endometrial Neoplasms
| Article | Year |
|---|---|
Phase 2 study of LY3023414 in patients with advanced endometrial cancer harboring activating mutations in the PI3K pathway.
Topics: Aged; Class I Phosphatidylinositol 3-Kinases; Class Ia Phosphatidylinositol 3-Kinase; Endometrial Neoplasms; Enzyme Activation; Female; Humans; Hyperglycemia; Hypoalbuminemia; Hypophosphatemia; Middle Aged; Mutation; Phosphatidylinositol 3-Kinases; Progression-Free Survival; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Pyridines; Quinolones; Signal Transduction; TOR Serine-Threonine Kinases; Treatment Outcome | 2020 |
Second-line dovitinib (TKI258) in patients with FGFR2-mutated or FGFR2-non-mutated advanced or metastatic endometrial cancer: a non-randomised, open-label, two-group, two-stage, phase 2 study.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Disease-Free Survival; Endometrial Neoplasms; Female; Humans; Kaplan-Meier Estimate; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Treatment Outcome | 2015 |
7 other study(ies) available for carbostyril and Endometrial Neoplasms
| Article | Year |
|---|---|
Synergistic effects of a combined treatment of PI3K/mTOR dual inhibitor LY3023414 and carboplatin on human endometrial carcinoma.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Endometrial Neoplasms; Female; Humans; Mice; Mice, Nude; Pyridines; Quinolones | 2021 |
Activity of the fibroblast growth factor receptor inhibitors dovitinib (TKI258) and NVP-BGJ398 in human endometrial cancer cells.
Topics: Animals; Antineoplastic Agents; Benzimidazoles; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cell Survival; Endometrial Neoplasms; Female; Humans; Inhibitory Concentration 50; Mice; Mutation; Phenylurea Compounds; Pyrimidines; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
The N550K/H mutations in FGFR2 confer differential resistance to PD173074, dovitinib, and ponatinib ATP-competitive inhibitors.
Topics: Adenosine Triphosphate; Animals; Benzimidazoles; Binding Sites; Biocatalysis; Cell Line; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Electrophoresis, Polyacrylamide Gel; Endometrial Neoplasms; Female; Humans; Imidazoles; Inhibitory Concentration 50; Models, Molecular; Mutation; Phosphorylation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Pyridazines; Pyrimidines; Quinolones; Receptor, Fibroblast Growth Factor, Type 2 | 2013 |
Combinatorial therapy using dovitinib and ICI182.780 (fulvestrant) blocks tumoral activity of endometrial cancer cells.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Cell Cycle; Cell Line, Tumor; Endometrial Neoplasms; Estradiol; Estrogen Receptor alpha; Female; Fulvestrant; Humans; Mice; Mice, SCID; Mutation; Neoplasms, Experimental; Quinolones; Receptor, Fibroblast Growth Factor, Type 2; Signal Transduction; Xenograft Model Antitumor Assays | 2014 |
Evaluating the potential bioactivity of a novel compound ER1626.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Apoptosis; Blotting, Western; Breast Neoplasms; Cell Cycle; Cell Movement; Cell Proliferation; Chick Embryo; Endometrial Neoplasms; Female; Flow Cytometry; Gene Expression Regulation, Neoplastic; Human Umbilical Vein Endothelial Cells; Humans; Indenes; Isoquinolines; Ketones; MCF-7 Cells; Molecular Structure; Quinolones; Receptors, Estrogen; Tetrazolium Salts; Thiazoles | 2014 |
Second-line dovitinib in metastatic endometrial cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Endometrial Neoplasms; Female; Humans; Quinolones; Receptor, Fibroblast Growth Factor, Type 2 | 2015 |
[FGF/FGFR blockade: New insights in endometrial cancer].
Topics: Benzimidazoles; Clinical Trials, Phase II as Topic; Endometrial Neoplasms; Female; Fibroblast Growth Factors; Humans; Molecular Targeted Therapy; Quinolones; Receptors, Fibroblast Growth Factor | 2015 |